Aster DM Healthcare: Q3 FY26 Performance Highlights and Merger Momentum

Aster DM Healthcare has concluded Q3 FY26 with a robust performance, demonstrating significant growth and strategic advancements, particularly in the context of its impending merger with Quality Care India Limited (QCIL). The company reported a consolidated revenue of INR 1,186 crore for the quarter, marking a 13% year-on-year increase. Operating EBITDA (excluding Kasargod) grew by an impressive 17% year-on-year to INR 237 crore, with margins expanding to 20.2% from 19.3% in Q3 FY25. Normalised PAT (excluding Kasargod) also saw a healthy 22% year-on-year growth, reaching INR 98 crore. These figures underscore the company's continued focus on clinical excellence, an improving case mix, and efficient cost management.

The combined entity, Aster DM Healthcare and QCIL, on a proforma basis, showcased even stronger results. Revenue for Q3 FY26 surged by 15% year-on-year to INR 2,366 crore, while Operating EBITDA increased by 22% to INR 503 crore. The combined operating EBITDA margin stood at a healthy 21%, with ROCE at 20.7%. This consistent performance across the first three quarters of FY26, characterized by steady patient volume growth (8-9% range) and sequential improvement in patient realizations, highlights the scale and complementary strengths of the two organizations ahead of their full integration. The company's strategic shift towards complex, high-value care is evident, with oncology revenues growing 27% year-on-year and contributing 11% to the Q3 FY26 revenue.

Aster DM Healthcare's strategic initiatives are clearly focused on expanding its footprint and enhancing clinical capabilities. The company added over 320 beds in the last year, bringing Aster's total capacity to 5,451 beds as of December 31, 2025. This includes the newly commissioned 263-bed Aster MIMS Kasargod, which has already shown encouraging ramp-up with an average of 400 outpatients per day and over 120 doctors onboarded. The broader pipeline includes an ambitious plan to add over 4,000 additional beds, taking the total bed capacity to 14,710+ beds through a balanced mix of greenfield and brownfield expansions. These projects, such as Aster Yeshwanthpur, Aster Capital Trivandrum, Aster Sarjapur, and Aster W&C Hyderabad, are strategically located to tap into under-penetrated markets and are expected to drive future growth.

The company is also making significant strides in digital transformation. The 'Aster Health' App has garnered over 3,50,000 downloads since its launch in November 2024, indicating strong adoption. Digital initiatives like Aster +HEALTH, AsterCare, and Aster Doctor Connect are designed to create a robust 'phygital' ecosystem, enhancing patient engagement, streamlining services, and improving operational efficiency. The recognition of Aster Digital India with the 'Innovation – New Initiatives Award' further validates these efforts. Clinically, Aster continues to push boundaries, with highlights including 2,000 brain and spine surgeries at Aster Whitefield, the first transcatheter Fontan procedure in Kerala, and the first robotic cancer surgery in the private sector in MIMS Kottakkal.

While the overall performance is strong, management transparently addressed a few challenges. The Karnataka & Maharashtra cluster experienced a softer quarter due to temporary volume moderation, scheme rationalization, and clinician movements. Proactive hiring and retention strategies are being implemented to address these. The Q3 margin dip for Aster was attributed to investments in clinical talent and higher material costs associated with complex oncology and cardiology procedures. However, management remains confident in achieving a 24-25% EBITDA margin for the combined entity in the next 2-3 years, driven by operational leverage and cost efficiencies.

The merger with Quality Care India Limited is a pivotal development. Post receipt of the no-objection letter from Stock Exchanges/SEBI, the company filed an application to NCLT in December 2025. The NCLT has directed that the shareholders' meeting be convened between February 27 and March 13, 2026, with the merger expected to be completed by Q1 FY27. This consolidation is anticipated to unlock significant synergies, including a 10-15% EBITDA upside potential, primarily through procurement centralization and an improved payor mix. The company's robust liquidity position, with INR 1,255 crore in cash and moderate gross debt of INR 631 crore, further strengthens its ability to fund these growth initiatives.

In conclusion, Aster DM Healthcare's Q3 FY26 results reflect a period of sustained growth, strategic expansion, and diligent execution. The company is not only delivering strong financial and operational performance but is also actively shaping its future through the transformative merger with Quality Care India Limited. With a clear vision for capacity expansion, clinical excellence, and digital integration, Aster DM Healthcare is well-positioned to strengthen its leadership in the Indian healthcare sector and create long-term value for all stakeholders.